Adverse effects: Specific ‐ dystonia during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ overall improvement (not any improvement) · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome ‐ overall improvement (not any improvement) compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Specific behaviour ‐ injury or threat of self to others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no improvement compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Adverse effect: Specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect: Specific ‐ hypotensive episode compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Adverse effect ‐ discontinued due to EPS · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect ‐ discontinued due to EPS compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia within 24 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Adverse effects · psychosis‐induced aggression or agitation
HALOPERIDOL may leads to higher adverse effects compared with OTHER ANTIPSYCHOTICS: g. QUETIAPINE (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquilisation or asleep Not asleep · patients with psychosis‐induced aggression or agitation
HALOPERIDOL probably leads to lower tranquillisation or asleep ‐ not asleep compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (moderate certainty).
1 finding from 1 review
Specific behaviours ‐ agitation >50% reduction in PANSS‐EC score · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in specific behaviours ‐ agitation >50% reduction in PANSS‐EC score compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review
Global outcome ‐ rated as severe ‐ CGI‐S · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ rated as severe ‐ CGI‐S compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ EPS during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: Specific ‐ EPS during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review